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Abstract
Background: vAcute pulmonary embolism (PE) is a life threatening disease. The treatment options depend on the
severity of the disease and the mortality varies widely depending on the severity of the condition. It is important to
identify patients who are at high risk of mortality. The aim of the present study was to explore the prognostic alues of
neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) for 30-day mortality in patients with acute PE.
Methods: The study included 321 patients admitted to our university hospital between January 2013 and May 2015 with
the diagnosis of acute PE. Multivariable risk models were developed to assess the predictive values of the NLR and PLR for
30-day mortality. Discrimination was evaluated using receiver operating characteristic (ROC) curves.
Results: Two hundred forty-eight patients met our selection criteria. Twenty of them died within 30 days of hospital
admission. NLR was found to be an independent predicator after other confounding factors were adjusted in the
model. For 1 unit of increase of NLR, the risk of 30-day mortality rose about 13 % (OR = 1.13,95 % CI: 1.04–1.23). The
area under ROC for NLR is 0.79 (95 %CI: 0.703–0.880). PLR was associated with 30-day mortality in univariate analysis
but the predicative ability diminished with inclusion of other predicators in multivariable model.
Conclusions: NLR is readily available predicator for short-term mortality. It could be a useful indicator for identifying
high risk population and guiding clinical management of acute PE.
Keywords: Pulmonary embolism, Neutrophil, Lymphocyte
Background
Acute pulmonary embolism (PE) is a serious disease asso-
ciated with high mortality rates despite advanced thera-
peutic options. It is estimated that the incidence rates of
PE is about 23 to 69 cases per 100,000 persons annually in
the United States [1]. PE accounts for 300,000 deaths in
Europe alone each year [2]. The short-term mortality varies
widely from 2 to 95 %, depending on the severity of the
disease [3]. It is important to identify prognostic markers
for those who are at greater risk of short-term death. In
2014, the European Society of Cardiology classified the se-
verity of acute PE based on the estimated PE-related early
mortality risk. Patients with suspected or confirmed shock
or persistent arterial hypotension are classified as high risk.
Patients without these clinical status are classified as “not
high risk” [4]. The classification has important implications
for PE diagnosis and treatment options. It is recommended
to use anti-coagulation treatment for low risk patients,
thrombolytic agents or embolectomy for high risk patients.
However, there is no explicit clinical criterion regarding
the use of anticoagulation or thrombolysis for patients with
intermediate risk of PE. Meyer and colleagues [5] con-
ducted a randomized, double-blind trial to compare treat-
ment effects of anticoagulation and thrombolysis for
patients with intermediate-risk of PE. It was found that
fibrinolytic therapy prevented hemodynamic instability but
increased the risk of hemorrhage and stroke. Sharifi
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discovered that low-dose tissue plasminogen activator is
safe and effective in the treatment of intermediate-risk PE
and could reduce the pulmonary artery pressure for more
than half year [6]. We believe that the accurate prediction
of high risk PE would help clinicians to identify appropriate
patients for thrombolytic therapy.
Many prognostic indicators have been developed for PE,
such as the simplified pulmonary embolism severity index
(sPESI), brain natriuretic peptide (BNP), N-terminal pro-
Brain Natriuretic Peptide (NT-pro-BNP), indications of
right ventricular dysfunction, heart-type fatty acid-binding
protein, and troponin concentrations. However, findings
for most of these indicators are inconsistent and many of
them are difficult to apply in the clinical setting or not
measured on routine basis, especially for developing coun-
tries where resources are limited.
Virchow [7] was first to describe that thrombus forma-
tion resulted from abnormalities in three areas including
blood flow, the vessel wall, and blood components. It is
well known that inflammation and thrombosis are inter-
related. Inflammation can cause endothelial damage, in-
crease procoagulant factors, inhibit natural anticoagulant
pathways and fibrinolytic activity [8]. Moreover, severe
hypoxia as result of blockage of pulmonary arteries
could increase activity of neurohormonal and adrenergic
system and induce the release of inflammatory cytokine.
Such response could exacerbate thrombosis and patients’
condition [9]. Kurtipek found the association between
NLR and PLR values and endothelial dysfunction in pa-
tients with PE. It is postulated that the endothelial dys-
function could play a role in the development of
cardiovascular events for PE patients [10].
Neutrophil to lymphocyte ratio (NLR) and platelet to
lymphocyte ratio (PLR) are found to be associated with
many inflammatory diseases. These indicators have been
used increasingly as new prognostic markers for risk
predication of cardiovascular disease and cancers [11–14].
Limited studies have explored the predicative abilities of
NLR and PLR on short-term mortality among patients
with acute PE [11, 15, 16]. However, some important con-
founding was not controlled in analysis and the predica-
tive abilities of NLR and PLR was not fully assessed.
Furthermore, NLR and PLR values are influenced by many
factors and the predictive ability could be confounded by
these factors. It is also important to exclude patients with
NLR or PLR-related diseases to avoid the interference of
disease status on NLR and PLR, such as severe infection
and hematological diseases. The prognostic values of these
indicators remain to be further evaluated. Accurate risk
stratification of acute PE are critical important to deter-
mine prognosis. The identification of novel prognostic
factors would help to guide interventions and avoid side
effects from inappropriate treatment. Both NLR and PLR
are readily available indicators during routine laboratory
tests. The prognostic values of these indicators would
allow active monitoring of disease progress and guide dis-
ease management among PE patients. The objective of the
current study is to explore the values of NLR and PLR in
predicating 30-days mortality in patients with acute PE.
Methods
We identified 357 adult patients with diagnosis of acute PE
at the First Affiliated Hospital of HeNan University of
Science and Technology, Henan, China, between January
2013 and May 2015. Thirty-six patients were lost-to-follow
up. A total of 321 patients were included in this study. The
diagnosis of PE was based on CT pulmonary angiogram
(CTPA) and suspected cases were excluded from the study.
The 30 day-mortality was identified through medical
records or contacting patients or their relatives regard-
ing the status of survival or date of death. Patients who
died within 30 days of hospital admission were defined
as short-term death.
Patients were excluded if they (1) received anticoagula-
tion or thrombolysis treatment before their blood test; (2)
or if they met one of the following conditions: a)
hematological diseases; b) diagnosed with any other disease
that could affect blood cell count (WBC > 20 × 109/L or
WBC < 3 × 109/L; Hgb < 80 g/L; Platelet < 80 × 109/L), such
as patients with clear evidence of active infection; c) had
blood transfusion during the past 2 weeks; d) received
immunosuppressant or steroid drugs in the last 2 weeks; e)
had acute coronary syndrome; e) advanced liver or renal
disease. Two hundred forty-eight patients met our inclu-
sion criteria.
Data was extracted from the hospital electronic database,
including patient characteristics, medical tests within 24 h
of hospital admission, and CTPA and echocardiograph
performed during the last 72 h of hospital admission. sPESI
was calculated based on age (≥80), history of cancer,
history of chronic cardiopulmonary disease/heart failure,
systolic blood pressure <100 mmHg, heart rate ≥110 bpm,
and arterial oxygen saturation <90 %. RVD was diagnosed
by ultrasonic cardiography (UCG-RVD) with the following
criteria (1) right ventricular and left ventricular diameter
ratio >1; right ventricular free wall motion amplitude <
5 mm, and (3) leftward shift of the ventricular septum [17].
The CT images of right ventricular dysfunction included
the axial diameter of the RV being larger than the diameter
of the left ventricular.
The statistical analysis was done using SPSS v.21. The
normality of distribution for continuous data was deter-
mined by Kolmogorov-Smirnov test. Student t test was
used to compare two groups of normally distributed
data, and Mann–Whitney U test was employed for no
normally distributed data. x2 test or Fisher’s Exact test
were performed for categorical data.
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Forward logistic regression was applied to deter-
mine the association between NLR or PLR and short-
term mortality, while controlling for potential con-
founding. Hosmer-Lemeshow goodness-of-fit test was
employed to assess the precision of the predictive
probabilities generated by the predicative model. It
assesses whether or not the observed mortality match
expected mortality based on expected probabilities. A
p value > 0.05 indicated acceptable predicative preci-
sion for each model.
The predicative accuracies of NLR and PLR were deter-
mined through receiver operating characteristic curves
(ROC). The area under the ROC curve reflects how good
the test is at discriminating between patients with or with-
out short-term death. A value >0.7 confirmed the useful-
ness of an indicator in predicting 30-daydeath. ROC was






Age (year) 66 (52–74) 75 (65–83) 0.001
Sex (Male) 126 (55.3 %) 13 (65 %) 0.400
Coronary heart disease 59 (25.9 %) 4 (20 %) 0.563
Diabetes 23 (10.1 %) 3 (15 %) 0.759
Hypertension 74 (32.5 %) 7 (35 %) 0.816
COPD 43 (18.9 %) 7 (35 %) 0.151
Chronic heart failure 41 (18.0 %) 5 (25 %) 0.984
Cancer 14 (6.1 %) 4 (20 %) 0.066
Had operation or bed rest immobilization <4 weeks 54 (23.7 %) 10 (50 %) 0.010
T (°C) 36.7 (36.4–37.1) 36.6 (36.4–36.8) 0.237
RR (min) 21 (20–23) 23 (20–25) 0.007
HR (min) 88 (80–96) 94 (86–108) 0.007
SBP (mmHg) 124 (110–140) 131 (121–150) 0.023
BNP (pg/ml) 209.25 (52.35–835.475) 1709.1 (676.1–4986) 0.000
LgBNP 2.29 ± 0.85 3.19 ± 0.66 0.000
UCG-RVD 70 (30.7 %) 12 (60 %) 0.008
CT-RVD 61 (26.8 %) 10 (50 %) 0.027
sPESI 0 (0–1) 1 (1–2) 0.000
WBC (109/L) 8.47 ± 3.05 9.146 ± 3.24 0.348
NEU (109/L) 5.70 (4.36–7.96) 7.79 (5.58–9.15) 0.035
LYM (109/L) 1.41 ± 0.71 0.74 ± 0.33 0.000
Monocytes (109/L) 0.46 (0.29–0.60) 0.37 (0.24–0.55) 0.285
HGB (g/L) 126.145 ± 19.11 111.05 ± 17.61 0.001
HCT 38.1 ± 5.49 33.7 ± 5.29 0.001
MCV 91.55 (88.10–94.95) 91.70 (89.35–93.83) 0.823
RDW (fl) 44.35 (41.6–49.0) 47.0 (45.0–50.5) 0.033
PLT (109/L) 228.5 (182.25–298.0) 228.5 (172.25–300.20) 0.868
MPV (fl) 9.26 ± 1.10 9.02 ± 1.046 0.346
PDW (fl) 16.1 (15.83–16.40) 16.00 (15.90–16.50) 0.967
NLR 4.43 (2.83–7.88) 10.00 (6.13–18.49) 0.000
PLR 172.25 (125.19–284.5) 371.94 (221.13–511.37) 0.000
COPD Chronic Obstructive Pulmonary Disease, T Body Temperature, RR Respiratory Rate, HR Heart Rate, SBP Systolic Blood Pressure, BNP Brain Natriuretic Peptide,
UCG-RVD Right Ventricular Dysfunction Diagnosed by Ultrasonic Cardiography, CT-RVD Right Ventricular Dysfunction Diagnosed by CT, WBC White Blood Cells, NEU
Neutrophil, LYM Lymphocyte, HGB Hemoglobin, HCT Hematocrit, MCV Mean Corpuscular Volume, RDW Red Cell Distribution Width, PLT Platelets, MPV Mean Platelet
Volume, PDW Mean Platelet Volumn, NLR Neutrophil to Lymphocyte Ratio, PLR Platelet to Lymphocyte Ratio
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used to determine the best cut-off points for prediction of
30-day mortality.
Results
Seventy-three patients were excluded because they didn’t
meet our criteria for blood cell count (32 cases), had un-
qualified echocardiograph (31 cases), received blood
transfusion (4 cases), had hematological diseases (3
cases), or received immunosuppressant or steroid drugs
(3 cases). A total of 248 patients met the selection cri-
teria and were included in the study. Twenty patients
died within 30 days of hospital admission. The charac-
teristics of the study population are presented in Table 1.
Patients who died within 30-days of admission are more
likely to be older, have history of operation or bed rest
immobilization within the last 4 weeks, have higher
heart or respiratory rate, right ventricular dysfunction,
higher systolic blood pressure, sPESI, BNP, neutrophil,
NLR, red cell distribution width (RDW), and PLR. The
lymphocyte (LYM), hemoglobin (HGB), and hematocrit
(HCT) were significantly lower among patients with
short-term morality (Table 1).
As the calculation of sPESI includes age, heart rate,
and systolic blood pressure, those risk factors were ex-
cluded from the risk models to avoid collinearity. BNP
was log transferred in the logistic regression as the dis-
tribution of BNP was highly skewed. The results of the
multivariate analysis show that NLR is an independent
predicator for 30-day mortality among patients with
acute PE. The probability of death increased about 13.2
% (OR = 1.13, 95 % CI: 1.04–1.23) with one unit of in-
crease of NLR (Table 2). LgBNP, sPESI, and HGB were
also significant predicators of 30-day mortality for PE
patients. The risk model has a good calibration with p
value of 0.721.
PLR is no longer a predictor in multivariate analysis
after other predicators were included in the model (OR =
1.002, 95 % CI: 0.997–1.008).
The areas under ROC is 0.792 (95 % CI: 0.703–0.880,
P < 0.001) for NLR and 0.789 (95 % CI:0.699–0.880, P <
0.001) for PLR. The cut-off value of 5.99 for NLR had
sensitivity and specificity values of 80 % and 66.7 %.
The sensitivity and specificity were 65 and 80.7 % for a
cut-off of 325.0 for PLR (Table 3).
Discussion
NLR represents the balance between neutrophils and
lymphocytes. It has been proposed as a new marker for
systemic inflammation [18]. Previous studies found that
increased NLR is associated with cardiovascular mortal-
ity [19]. The high NLR is results of increased neutrophil
count and decreased lymphocyte count. The elevated
serum cortisol levels, as a response to stress, may ac-
count for such change. The inflammation procedure
could stimulate the production of neutrophil and speed
up the apoptosis of lymphocytes. Moreover, the in-
creased number of neutrophils is associated with inflam-
matory process which could contribute to thrombotic
state. Jo found that systemic inflammatory response syn-
drome criteria were significantly more common for PE
patients who died within 30 days of hospital admission
[20]. It reveals the role of systemic inflammation for
short-term mortality among PE patients. The results of
this study confirm the hypothesis that NLR is a signifi-
cant risk predictor of 30-day mortality. It was observed
that increased neutrophil and decreased lymphocyte
count within deceased group. The NLR had good dis-
crimination and calibration for short-term morality,
demonstrating its usefulness in predicating short-term
mortality. The predicative ability was independent of
many other predicators included in the model. The re-
sult of our study is consistent with recently finding,
which indicates that NLR is useful for risk stratification
in patients with venous thromboembolism [21]. The risk
of short-term death was increased by about 13 % with
increase of every unit of NLR. By evaluating NLR, clini-
cians may identify high risk patients among those who
would be classified as low risk or intermediate risk on
the basis of other predicators. Treatment plans can be
adjusted based on calculated NLR to reduce the possibility
of short-term death. In addition, NLR is measured on rou-
tine basis. It has potential to be used to monitor the dis-
ease progress for PE patients.
Recently, PLR has been considered as a new marker of
systemic inflammation [22]. It was found that PLR has
better prognostic value than platelet or lymphocytes
alone in predicting certain cardiovascular diseases [23].
We found that PLR was significantly higher for patients
Table 2 Multivariate regression results of short-term death for
acute pulmonary embolism
Risk factors OR 95 % CI P
Lower Upper
NLR 1.132 1.044 1.228 0.003
HGB 0.942 0.907 0.979 0.003
LgBNP 2.913 1.247 6.804 0.014
sPESI
Goodness-of-fit test (p)
1.936 1.121 3.345 0.018
0.721
OR odds ratio, CI confidence interval
Table 3 Values of area under the ROC curve (AUC), sensitivity and
specificity for the optimal cut-off point of NLR and PLR for predicting
short-term death among patients with acute pulmonary embolism
Predicators AUC (95 % CI) P Cut-off Sensitivity Specificity
NLR 0.792 (0.703–0.880) 0.000 5.99 80 % 66.70 %
PLR 0.789 (0.699–0.880) 0.000 325.0 65 % 80.70 %
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who died within 30-days of hospital admission in the
univariate analysis. However, the predictive ability di-
minished after confounding factors were included in the
model. One study found that PLR was significantly cor-
related with sPESI [24]. It indicates that the prognostic
value observed in univariate analysis may not be inde-
pendent predicator for 30-day mortality. In addition, the
sensitivity of PLR at optimal cut-off point is relatively
low considering the severity of the complication. PLR
might not be a good predicator for short-term mortality.
RDW was found to be a diagnostic measure for patient
with suspected PE and it could aid in the risk stratifica-
tion of patients with PE [9]. The results of our study
show that predictability of NLR is not confounded by
RDW. It is consistent with their finding that RDW is not
corrected with NLR. NLR could add additional value in
predicating short-term mortality for patients with PE.
Limitations
This study had some limitations. This is a single center
retrospective study with a limited sample size. For some
patients, it is difficult to differentiate PE with pulmonary
infection. The results of this study results could be
biased by such misclassification. Troponin is considered
an important predictor for PE. This indicator was not in-
cluded in our analysis, as this indicator was not per-
formed for about half of the study participants. Some PE
patients might have unstable COPD. The severity of
COPD is associated with PE as well as death. Our data
doesn’t contain detailed classification of COPD. Al-
though COPD was controlled in multivariate analysis,
our study results could still be biased by COPD severity.
Further studies are required to evaluate the stages of
COPD and NLR on short-term mortality for PE patients.
Conclusions
NLR is an independent predicator for short-term mor-
tality among PE patients. It enable sassessing the severity
of PE, and could guide the clinical management of PE.
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